Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy
Authors' conclusion
CAPA is an indicator of a protracted course of a COVID-19 infection. No benefit of pre-emptive screening was observed
Study context
- Population
- ICU patients with COVID-19 who underwent diagnostics for CAPA, Netherlands/Belgium, September 2020-April 2021
- Participants
- 1,977 patients
- Exposure
- CAPA vs no CAPA; pre-emptive screening vs reactive diagnostic strategy
- CAPAn = 295
- Outcome
- Incidence of CAPA
Methodological detailsobservational, multicentre, Corticosteroids given to 97.1% and anti-IL-6 to 23.5% of patients
- Observational
- Multicentre
- Corticosteroids given to 97.1% and anti-IL-6 to 23.5% of patients
Main finding
As reported in the abstract
CAPA incidence
CAPA
14.9%
295
Observational data: associations, not effects.
Further findings
Mortality · 90 days
P = 0.008
- Time from ICU admission to CAPA diagnosis
- 12 · median · days
- Mortality: 145/222 vs 176/328
Risk factors for CAPA
- EORTC/MSGERC host factors or anti-IL-6 with or without corticosteroids not risk factors for CAPA
Pre-emptive screening vs reactive diagnostic strategy
- Pre-emptive screening not associated with earlier diagnosis or reduced mortality
Original publication
Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. J Crit Care. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →